Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
6MP or Calcitriol vs. Purinethol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Delayed Release 6MP or Calcitriol vs. Purinethol | DRUG | - |
Inclusion Criteria: * Male or Female patients, aged 18-75 years with moderate Crohn's Disease (CDAI score \>=220 and \<=400 at screening), with or without adjunctive mesalamine treatment, 12 with involvement of the ileum and three without ileal involvement * Definitive diagnosis of active inflammat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
6MP or Calcitriol vs. Purinethol is an investigational small molecule being studied for the treatment of Crohn's Disease. It is being evaluated in a Phase 1 clinical trial that has been completed. The drug is intended for patients with Crohn's Disease, a type of inflammatory bowel disease.
The specific molecular target of 6MP or Calcitriol vs. Purinethol is not disclosed in the available information. The drug is being studied for its efficacy in treating Crohn's Disease, but the exact mechanism of action has not been specified in the clinical trial data.
6MP or Calcitriol vs. Purinethol is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker symbol TEVA. The drug is currently in clinical development for Crohn's Disease.
6MP or Calcitriol vs. Purinethol is in Phase 1 clinical development. The Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation for Crohn's Disease.
6MP or Calcitriol vs. Purinethol has been studied in one clinical trial with the identifier NCT00287170. This Phase 1 trial, titled 'Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease,' was completed in Israel and enrolled 15 participants aged 18 years and older.
6MP or Calcitriol vs. Purinethol is a drug being studied in comparison with Purinethol, but it is not the same drug. The name indicates a study comparing 6MP or Calcitriol against Purinethol. The drug is being developed by Teva Pharmaceutical Industries Limited for Crohn's Disease.